non-small cell lung cancer

Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending
Fierce Pharma
Merck
Keytruda
drug pricing
non-small cell lung cancer
Flag link:
FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers
FDA approves diagnostic that simultaneously screens for multiple cancer biomarkers
Drug Delivery Business News
FDA
Thermofisher
diagnostics
biomarkers
non-small cell lung cancer
Oncomine Dx Target Test
Flag link:
Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Novartis picks up FDA approval for targeted lung cancer meds Tafinlar, Mekinist
Fierce Pharma
Novartis
FDA
Tafinlar
Mekinist
non-small cell lung cancer
BRAF V600
Flag link:
Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Endpoints
Incyte
ASCO 2017
epacadostat
non-small cell lung cancer
Keytruda
Flag link:
Novartis' Zykadia piles pressure on Pfizer's Xalkori, Roche's Alecensa with new lung cancer nod
Novartis' Zykadia piles pressure on Pfizer's Xalkori, Roche's Alecensa with new lung cancer nod
Fierce Pharma
Novartis
Zykadia
Pfizer
Xalkori
Roche
Alecensa
non-small cell lung cancer
Flag link:
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Endpoints
Incyte
epacadostat
ASCO 2017
Merck
Keytruda
non-small cell lung cancer
Flag link:
Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
Endpoints
Syndax Pharma
clinical trials
entinostat
non-small cell lung cancer
Flag link:
Astellas scraps NSCLC program after look at phase 3 data
Astellas scraps NSCLC program after look at phase 3 data
Fierce Biotech
Astellas
non-small cell lung cancer
clinical trials
ASP8273
Flag link:
AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
Endpoints
AstraZeneca
clinical trials
durvalumab
Imfinzi
non-small cell lung cancer
Flag link:
Has Merck Lucked Into A $10 Billion Drug?
Has Merck Lucked Into A $10 Billion Drug?
Forbes
Merck
Keytruda
bladder cancer
non-small cell lung cancer
Flag link:
OncoMed racks up three straight clinical disasters as lead drug implodes
OncoMed racks up three straight clinical disasters as lead drug implodes
Endpoints
OncoMed
demcizumab
Celgene
clinical trials
non-small cell lung cancer
Flag link:
Roche unit Genentech takes on Pfizer with new lung cancer data
Roche unit Genentech takes on Pfizer with new lung cancer data
BioPharma Dive
Roche
Genentech
Pfizer
Xalkori
Alecensa
non-small cell lung cancer
Flag link:
Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials
Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials
Fierce Pharma
Merck
Bristol-Myers Squibb
Incyte
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
FDA Approves Astra's Lung Cancer Drug
FDA Approves Astra's Lung Cancer Drug
Investopedia
AstraZeneca
FDA
Tagrisso
non-small cell lung cancer
Flag link:
AstraZeneca’s Lung Cancer Drug Secures China Approval
AstraZeneca’s Lung Cancer Drug Secures China Approval
Investopedia
AstraZeneca
China
Tagrisso
non-small cell lung cancer
Flag link:
Struggling Heat gets a warm response to a snapshot on cancer vax data
Struggling Heat gets a warm response to a snapshot on cancer vax data
Endpoints
Heat Biologics
vaccines
HS-110
non-small cell lung cancer
Bristol-Myers Squibb
Opdivo
Flag link:
Pfizer, Merck KGaA Delay Lung Cancer Drug Trial Outcome
Pfizer, Merck KGaA Delay Lung Cancer Drug Trial Outcome
Investopedia
Pfizer
Merck KGaA
clinical trials
avelumab
non-small cell lung cancer
Flag link:
The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up
The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up
Endpoints
FDA
Novartis
Zykadia
ALK-positive non-small cell lung cancer
non-small cell lung cancer
Roche
Alecensa
Flag link:
Roche cancer drug taking bite out of Bristol's Opdivo
Roche cancer drug taking bite out of Bristol's Opdivo
Yahoo/Reuters
Roche
Bristol-Myers Squibb
Tecentriq
non-small cell lung cancer
Opdivo
Flag link:
Label Expansion May Boost Revenues for AstraZeneca’s Tagrisso
Label Expansion May Boost Revenues for AstraZeneca’s Tagrisso
Market Realist
AstraZeneca
Tagrisso
non-small cell lung cancer
Flag link: